KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,258,938 | +22.6% | 234,573 | +14.6% | 1.83% | +55.3% |
| Q2 2023 | $1,842,480 | +197.8% | 204,720 | +160.1% | 1.18% | +179.8% |
| Q1 2023 | $618,739 | +16.3% | 78,720 | 0.0% | 0.42% | +14.7% |
| Q4 2022 | $532,147 | -53.4% | 78,720 | 0.0% | 0.37% | -49.7% |
| Q3 2022 | $1,142,000 | +47.4% | 78,720 | 0.0% | 0.73% | +37.0% |
| Q2 2022 | $775,000 | -33.2% | 78,720 | 0.0% | 0.53% | -3.3% |
| Q1 2022 | $1,160,000 | +11.4% | 78,720 | 0.0% | 0.55% | +78.6% |
| Q4 2021 | $1,041,000 | -24.2% | 78,720 | 0.0% | 0.31% | -30.0% |
| Q3 2021 | $1,374,000 | -27.1% | 78,720 | 0.0% | 0.44% | -24.9% |
| Q2 2021 | $1,886,000 | – | 78,720 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |